0000950170-24-043842.txt : 20240411
0000950170-24-043842.hdr.sgml : 20240411
20240411211041
ACCESSION NUMBER: 0000950170-24-043842
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231214
FILED AS OF DATE: 20240411
DATE AS OF CHANGE: 20240411
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Loew Caroline
CENTRAL INDEX KEY: 0001989488
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41837
FILM NUMBER: 24839817
MAIL ADDRESS:
STREET 1: MURAL ONCOLOGY LTD.
STREET 2: 10 EARLSFORT TERRACE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 T380
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mural Oncology plc
CENTRAL INDEX KEY: 0001971543
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 EARLSFORT TERRACE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 T380
BUSINESS PHONE: 353 1 905 8020
MAIL ADDRESS:
STREET 1: 10 EARLSFORT TERRACE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 T380
FORMER COMPANY:
FORMER CONFORMED NAME: Mural Oncology Ltd
DATE OF NAME CHANGE: 20230403
FORMER COMPANY:
FORMER CONFORMED NAME: Pistachiovale Ltd
DATE OF NAME CHANGE: 20230329
4/A
1
ownership.xml
4/A
X0508
4/A
2023-12-14
2023-12-18
0001971543
Mural Oncology plc
MURA
0001989488
Loew Caroline
C/O MURAL ONCOLOGY PLC
10 EARLSFORT TERRACE
DUBLIN 2
L2
D02 T380
IRELAND
true
true
false
false
Chief Executive Officer
false
Stock Option (right to buy)
5.4809
2023-12-14
4
A
false
379690
A
2033-07-02
Ordinary Shares
379690
379690
D
This amendment to Form 4 is being filed solely to correct the exercise price of the granted option, which was previously reported as being $3.61 due to a scrivener's error.
Represents an option award originally granted by Alkermes plc ("Alkermes") that was converted into an option award of Mural Oncology plc (the "Issuer") in connection with the spin-off of the Issuer from Alkermes.
This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of July 5, 2023, subject to the reporting person's continued service with the Issuer.
/s/ Maiken Keson-Brookes, attorney-in-fact for Caroline Loew
2024-04-11